Tarveda Therapeutics Announces Presentation at 2019 BIO International Convention

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tarveda Therapeutics®, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumor malignancies, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2019 BIO International Convention occurring June 3-6, 2019 in Philadelphia, PA. The presentation will take place on Wednesday, June 5, 2019 at 2:00 PM ET in Theater 3 in the Pennsylvania Convention Center.

Mr. Fromkin will provide an overview of the Company’s Pentarin platform. Pentarins are precision oncology medicines that are designed to rapidly penetrate solid tumors, selectively bind to the desired tumor targets, and accumulate their anti-cancer payloads in the tumors while minimizing exposure of healthy tissues. Mr. Fromkin will also discuss Tarveda’s two clinical stage programs including PEN-866, which is the first miniature drug conjugate from Tarveda’s Heat Shock Protein 90 (HSP90) binding conjugate platform. PEN-866 is currently being evaluated in an ongoing Phase 1/2a clinical trial in patients with advanced solid tumors. PEN-221 is currently being evaluated in a Phase 1/2a clinical trial in somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors and is designed to rapidly penetrate deep into solid tumors where it is highly selective for SSTR2 and accumulates its potent DM1 payload.

To schedule a meeting with Tarveda’s management team at the Convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact bd@tarvedatx.com.

About Tarveda Therapeutics®, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company that is developing and discovering a new class of potent and selective precision oncology medicines for the treatment of patients with solid tumor malignancies. We are developing our proprietary Pentarins® (miniature drug conjugates) to enhance the effectiveness of promising anti-cancer payloads that have struggled without their selective targeting to solid tumors. http://www.tarvedatx.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005368/en/